Hormonal
GLP-1 agonist medications (e.g., semaglutide 2.4 mg) produce clinically significant weight loss (approx. 12.4-12.5%) and improve multiple health markers independent of weight loss, but their use carries risks of medicalizing weight and increasing social stigma.
GLP-1 medications like semaglutide are highly effective for weight loss and improving health markers, but they are not without social costs. If you consider using them, be aware that you may face stigma from others who view it as an 'easy way out' or fear that it medicalizes your body. A patient-centered approach focuses on your overall health and well-being rather than just the number on the scale, and acknowledges these social realities.
the STEP 1 trial of 2.4 mg of semaglutide observed a 12.4% weight loss difference between the semaglutide vs. placebo groups across 68 weeks of treatment... GLP-1 agonist medications also risk medicalizing weight and increasing weight stigma
Why this rating
Based on cited Phase 3 clinical trials (STEP 1, STEP 5) and FDA approvals.
Source
Behavioral medicine in the GLP-1 era
A. Janet Tomiyama · Annals of Behavioral Medicine · 2024
DOI 10.1093/abm/kaae069
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →